Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

I was really puzzled about the collaboration that ADXS and Vaithi Arumugaswami's lab announced yesterday. Several points:
1) UCLA's Vaithi Arumugaswami has no background or expertise in GBM. Look at his CV, lab profile and see that he's a veterinarian, completed his PhD cell biology and worked on ZIKA virus.
https://bio.csmc.edu/view/14998/Vaithilingaraja-Arumugaswami.aspx
2) The funding of this "collab" is going to be an issue. Obviously, Arumugaswami has no internal funding for this project, and the pre-clinical work will likely be funded by ADXS once again. Instead of being laser focused on HOT and NEO, they now started this glioblastoma exploration? Did we just forget they canned several clinical programs (Aim2Cerv included) to save cash? Now they want to through good money after some decades away project? What the heck that is supposed to mean?

No surprise the stock cratered yesterday. In addition to a bull trap orchestrated masterfully by a fund or two, they got help from the ADXS management. Two PRs within few days and we now go back to low 20s. Looks like to cash deal is coming anytime soon.